Email Alert | RSS

Journal of Peking University(Health Sciences) ›› 2019, Vol. 51 ›› Issue (3): 542-547. doi: 10.19723/j.issn.1671-167X.2019.03.025

Previous Articles     Next Articles

Detection of preoperative chemoradiotherapy sensitivity molecular characteristics of rectal cancer by transcriptome second generation sequencing

Wei ZHANG1,Ying-jiang YE2,Xian-wen REN3,Jing HUANG4,Zhan-long SHEN1△()   

  • Received:2019-03-25 Online:2019-06-18 Published:2019-06-26
  • Supported by:
    Supported by the Fundamental Research Funds for the Central Universities: Peking University Clinical Medicine Plus X-Young Scholars Project (PKU2018LCXQ021)

RICH HTML

   

PDF (PC)

Abstract: Objective: To detect the preoperative chemoradiotherapy sensitivity molecular characteristics of rectal cancer by transcriptome second generation sequencing.Methods: The clinicopathological data of 30 patients with locally advanced rectal cancer were collected prospectively, including 9 indicators (general conditions, imaging data before radiotherapy and chemotherapy, pathological data of biopsy before radiotherapy and chemotherapy, and tumor differentiation degree, etc.), in order to analyze the correlation between them and tumor regression grading (TRG) after radiotherapy and chemotherapy for rectal cancer. At the same time, frozen specimens of colonoscopy biopsy before neoadjuvant therapy were collected from these 30 patients, and transcriptome second-generation sequencing was performed for bioinformatics analysis to screen out the genes that might drive the radio chemotherapy sensitivity of rectal can-cer. Results: Among the 30 patients with rectal cancer, 9 had complete pathological remission, 12 had partial remission, and 9 had poor remission. The degree of pathological TRG remission after radiotherapy and chemotherapy for rectal cancer was negatively correlated with the preoperative MRI T stage (P=0.046), and positively correlated with preoperative MRI rectal cancer extravascular invasion (EMVI) (P=0.003). Transcriptome second-generation sequencing of the obtained 217 transcripts (P<0.05) for signal pathway enrichment analysis, and multiple cell signal transduction pathways related to antigen presentation could be found. The high expression of HSPA1A, HSPA1B and EXOSC2 was positively correlated with postoperative pathological remission (P<0.05). The high expression of DNMBP, WASH8P, FAM57A, and SGSM2 was positively correlated with postoperative pathological remission (P<0.05).Conclusion: Preoperative NMR detection of extra-tumoral vascular invasion (EMVI-positive) in patients with rectal cancer was significantly better than that of EMVI-negative patients after chemoradiotherapy. Patients with high expressions of HSPA1A, HSPA1B and EXOSC2 had poor postoperative pathological remission, while patients with high expressions of genes, such as DMNMB, WASH8P, FAM57A, and SGSM2 had good postoperative pathological remission. Based on the molecular characte-ristics of rectal cancer radiotherapy and chemotherapy, attempts to block or enhance the molecular pathways associated with chemosensitivity of rectal cancer, are to be made to further explore new candidate therapeutic targets that can increase the sensitivity of radiotherapy and chemotherapy for rectal cancer.

Key words: Rectal neoplasms, Neoadjuvant therapy, Transcriptome sequencing, Tumor regression grading

CLC Number: 

  • R735.3

Table 1

Relationship between clinicopathological data and TRG classification in patients with colorectal cancer"

Clinical pathological data Number Complete remission Partial emission Non-remission P value
n % n % n %
Total 30 9 30.0 12 40.0 9 30.0
Gender 0.860
Male 23 6 26.1 10 43.5 7 30.4
Female 7 3 33.3 2 64.3 2 22.2
Age/years 0.732
<65 17 4 23.5 7 41.2 6 35.3
≥65 13 5 38.5 5 38.5 3 23.0
BMI >0.999
<18.5 1 0 0 1 100.0 0 0
18.5-23.9 11 4 36.4 4 36.4 3 27.2
≥24 18 5 27.8 7 38.9 6 33.3
MRI T staging 0.046
cT1 1 1 100.0 0 0 0 0
cT2 2 1 50.0 1 50.0 0 0
cT3 13 5 38.5 6 46.2 2 15.3
cT4 14 1 7.1 5 35.7 8 57.2
MRI N staging 0.926
cN0 16 5 31.3 6 37.5 5 31.3
cN+ 11 3 27.2 4 36.4 4 36.4
Undecided 3 1 33.3 2 66.7 0 0
EMVI 0.003
Positive 17 8 47.1 8 47.1 1 5.8
Negative 13 1 7.7 4 30.8 8 61.5
Tumormaximum diameter 0.898
>5 cm 11 3 27.2 4 36.4 4 36.4
≤5 cm 19 6 31.6 8 42.1 5 26.3
Pathological type 0.867
Adenocarcinoma 21 6 28.6 9 42.4 6 28.6
Mucinous adenocarcinoma 8 3 37.5 2 25.0 3 37.5
Signet ring cell carcinoma 1 0 0 1 100 0 0
Degree of differentiation 0.923
Low 6 1 16.7 3 50.0 2 33.3
Middle 11 3 27.2 5 45.5 3 27.2
High 13 5 38.5 4 30.7 4 30.7

Figure 1

Transcript expression associated with pathologic remission of preoperative chemoradiotherapy CR, complete remission group; PR, partial remission group; NR, non-remission group; TPM, transcripts per million."

[1] Park IJ, You YN, Agarwal A , et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer[J]. J Clin Oncol, 2012,30(15):1770-1776.
doi: 10.1200/JCO.2011.39.7901
[2] Dworak O, Keilholz L, Hoffmann A . Pathological features of rectal cancer after preoperative radiochemotherapy[J]. Int J Colorectal Dis, 1997,12(1):19-23.
doi: 10.1007/s003840050072
[3] Rödel C, Martus P, Papadoupolos T , et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer[J]. J Clin Oncol, 2005,23(34):8688-8696.
doi: 10.1200/JCO.2005.02.1329
[4] Fokas E, Liersch T, Fietkau R , et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial[J]. J Clin Oncol, 2014,32(15):1554-1562.
doi: 10.1200/JCO.2013.54.3769
[5] Smith JD, Ruby JA, Goodman KA , et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy[J]. Ann Surg, 2012,256(6):965-972.
doi: 10.1097/SLA.0b013e3182759f1c
[6] Postmus I, Trompet S, Deshmukh HA , et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL choleste-rol response to statins[J]. Nat Commun, 2014,5:5068.
doi: 10.1038/ncomms6068
[7] Williamson JS, Jones HG, Williams N , et al. Extramural vascular invasion and response to neoadjuvant chemoradiotherapy in rectal cancer: influence of the CpG island methylator phenotype[J]. World J Gastrointest Oncol, 2017,9(5):209-217.
[8] Chand M, Swift RI, Tekkis PP , et al. Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer[J]. Br J Cancer, 2014,110(1):19-25.
doi: 10.1038/bjc.2013.603
[9] Birlik B, Obuz F, Elibol FD , et al. Diffusion-weighted MRI and MR-volumetry: in the evaluation of tumor response after preoperative chemoradiotherapy in patients with locally advanced rectal cancer[J]. Magn Reson Imaging, 2015,33(2):201-212.
doi: 10.1016/j.mri.2014.08.041
[10] McCawley N, Clancy C, O’Neill BD , et al. Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: A systematic review and meta-analysis[J]. Dis Colon Rectum, 2016,59(12):1200-1208.
doi: 10.1097/DCR.0000000000000635
[11] Agarwal A, Chang GJ, Hu CY , et al. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy[J]. Cancer, 2013,119(24):4231-4241.
doi: 10.1002/cncr.28331
[12] Maas M, Nelemans PJ, Valentini V , et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data[J]. Lancet Oncol, 2010,11(9):835-844.
doi: 10.1016/S1470-2045(10)70172-8
[13] Gérard JP, Chamorey E, Gourgou-Bourgade S , et al. Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial[J]. Radiother Oncol, 2015,115(2):246-252.
doi: 10.1016/j.radonc.2015.04.003
[14] Chen MB, Wu XY, Yu R , et al. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer[J]. PLoS One, 2012,7(9):e45388.
doi: 10.1371/journal.pone.0045388
[15] D’Angelo E, Zanon C, Sensi F , et al. miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma[J]. J Clin Pathol, 2018,71(4):344-350.
doi: 10.1136/jclinpath-2017-204690
[16] Agostini M, Zangrando A, Pastrello C , et al. A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients[J]. Cancer Biol Ther, 2015,16(8):1160-1171.
doi: 10.1080/15384047.2015.1046652
[17] Scott JG, Berglund A, Schell MJ , et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study[J]. Lancet Oncol, 2016,18(2):202-211.
[18] Regine WF, Winter KA, Abrams RA , et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial[J]. JAMA, 2008,299(9):1019-1026.
doi: 10.1001/jama.299.9.1019
[19] Coveler AL, Richard P, Apisarnthanarax S , et al. Is there a best radiosensitizing agent in the treatment of locally advanced rectal cancer?[J]. Current Colorectal Cancer Reports, 2016,12(4):189-200.
doi: 10.1007/s11888-016-0324-7
[20] Aschele C, Cionini L, Lonardi S , et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the star-01 rando-mized phase Ⅲ trial[J]. J Clin Oncol, 2011,29(20):2773-2780.
doi: 10.1200/JCO.2010.34.4911
[1] Yan XIONG,Bo ZHANG,Li-gong NIE,Shi-kai WU,Hu ZHAO,Dong LI,Ji-ting DI. Thoracic SMARCA4-deficient undifferentiated tumor-pathological diagnosis and combined immune checkpoint inhibitor treatment [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 351-356.
[2] Li LIANG,Xin LI,Lin NONG,Ying DONG,Ji-xin ZHANG,Dong LI,Ting LI. Analysis of microsatellite instability in endometrial cancer: The significance of minimal microsatellite shift [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 254-261.
[3] DING Ting-ting,ZENG Chu-xiong,HU Li-na,YU Ming-hua. Establishment of a prediction model for colorectal cancer immune cell infiltration based on the cancer genome atlas (TCGA) database [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 203-208.
[4] Xu-chu ZHANG,Jian-hua ZHANG,Rong-fu WANG,Yan FAN,Zhan-li FU,Ping YAN,Guang-yu ZHAO,Yan-xia BAI. Diagnostic value of 18F-FDG PET/CT and tumor markers (CEA, CA19-9, CA24-2) in recurrence and metastasis of postoperative colorectal moderately differentiated adenocarcinoma [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1071-1077.
[5] CHEN Yang, WANG Yan-rong, SHI Yan, DAI Guang-hai. Prognostic value of chemotherapy-induced neutropenia in metastatic colon cancer patients undergoing first-line chemotherapy with FOLFOX [J]. Journal of Peking University(Health Sciences), 2017, 49(4): 669-674.
[6] LIU Yan-xia, YANG Xue-song, FU Wei, YAO Hong-wei. Association of single nucleotide polymorphism rs6983267 with ulcerative colitis and colorectal cancer [J]. Journal of Peking University(Health Sciences), 2016, 48(6): 994-999.
[7] SI Jing-wen, WANG Li, BA Xiao-jun, ZHANG Xu, DONG Ying, ZHANG Ji-xin, LI Wen-ting, LI Ting. Clinicopathological screening of Lynch syndrome: a report of 2 cases and literature review [J]. Journal of Peking University(Health Sciences), 2015, 47(5): 858-864.
[8] LI Zhi-Hong, LIU Dan, HE Zi-Jing, FAN Zhi-Yi. Influence of dexamethasone on the incidence of postoperative nausea and vomiting in breast cancer patients with neoadjuvant chemotherapy [J]. Journal of Peking University(Health Sciences), 2015, 47(4): 685-689.
[9] YUAN Chun-hui, XIU Dian-rong, GE Hui-yu, TAN Shi, WANG Hang-yan, ZHANG Li, ZHANG Tong-lin. Ultrasound guided ablation therapy of hepatic colorectal metastases: initial experience of real time virtual sonography navigation system [J]. Journal of Peking University(Health Sciences), 2013, 45(6): 956-959.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd